Global Epigenetics Drugs Market – Industry Trends and Forecast to 2030

Análise e dimensão do mercado de medicamentos epigenéticos

Os medicamentos epigenéticos são utilizados como inibidores precisos para cada condição epigenética, em que a identificação de medicamentos epigenéticos é importante na descoberta de medicamentos para condições epigenéticas. O mercado ainda está na sua infância; muito poucos medicamentos epigenéticos são recomendados e aprovados para condições de saúde graves. O valor potencial de mercado para os medicamentos epigenéticos é enorme em comparação com outras tecnologias em funcionamento.

A Data Bridge Market Research analisa uma taxa de crescimento no mercado de fármacos epigenéticos no período de previsão 2023-2030. O CAGR esperado do mercado de medicamentos epigenéticos tende a rondar os 19,3% no período de previsão mencionado. O mercado foi avaliado em 9.408,7 milhões de dólares em 2022 e cresceria até aos 38.605,8 milhões de dólares até 2030. Além dos insights de mercado, como o valor de mercado, a taxa de crescimento, os segmentos de mercado, a cobertura geográfica, os participantes do mercado e cenário de mercado, o O relatório de mercado com curadoria da equipa de pesquisa de mercado da Data Bridge inclui também uma análise especializada aprofundada, epidemiologia dos doentes, análise de pipeline, análise de preços e estrutura regulamentar.

Âmbito e segmentação do mercado de fármacos epigenéticos

Definição de mercado

A epigenética significa, geralmente, as modificações externas ao ADN que transformam os genes em "ligados" ou "desligados". Estas modificações geralmente não levam a qualquer alteração na sequência do ADN, no entanto afetam a leitura dos genes das células. Enfatiza o estudo do nível celular e dos caracteres fisiológicos herdados pelas células-filhas sem provocar qualquer interrupção na sequência do ADN. Portanto, a epigenética proporciona alterações que se apresentam na expressão génica, sendo estas consideradas importantes mecanismos da epigenética. Portanto, os medicamentos epigenéticos são utilizados para combater a desregulação de eventos epigenéticos causados ​​por condições patológicas que podem desenvolver outras doenças crónicas.

Dinâmica do mercado de medicamentos epigenéticos

Motoristas

• Aumento de casos de cancro

O cancro está se espalhando pelo mundo. De acordo com a OMS, em 2020 ocorreram cerca de 2,1 milhões de novos casos de cancro em todo o mundo. 70% das mortes por cancro ocorrem em países de baixo e médio rendimento. O cancro mata 1 em cada 4 americanos. A metilação descontrolada do ADN pode causar e promover o cancro. A epigenética descobriu novos tratamentos contra o cancro. Existem vários estudos de investigação sobre o cancro utilizando a epigenética que são bem financiados. Os medicamentos baseados na epigenética são benéficos contra um certo tipo de cancro. A epigenética tem como alvo apenas as células danificadas e cancerígenas do hospedeiro.

• Estratégias crescentes para os lançamentos de medicamentos

Os principais players do mercado que operam no mercado estão a concentrar-se em estratégias de crescimento, como aprovações de produtos, para impulsionar o crescimento do mercado durante o período de previsão. Por exemplo, em novembro de 2021, a Epizyme, Inc., uma empresa biofarmacêutica totalmente integrada e em fase comercial que desenvolve e fornece novas terapias epigenéticas, anunciou que a FDA dos EUA concedeu a designação Fast Track ao EZM0414. É um agente experimental utilizado para tratar doentes adultos com linfoma difuso de grandes células B (DLBCL) recidivante ou refratário.

Oportunidades

• Maior desenvolvimento de novos candidatos a fármacos epigenéticos

Several companies operating in the market are widely engaged in developing new epigenetic drug candidates that are expected to create growth opportunities for the market during the forecast period. For instance, in April 2021, Celleron Therapeutics, a U.K.-based personalized medicines developing company, published the latest positive results of zabinostat. Furthermore, Zabinostat is an epigenetic immune regulator that activates genes involved in tumour antigen presentation and acts by stimulating cancer cells to present tumour antigens to T-lymphocytes, thus overcoming immune evasion. In addition to this, in CAROSELL Phase 2 clincal study, Celleron Therapeutics is investigating zabinostat and nivolumab combination treatment used for treating patients with microsatellite-stable colorectal cancer (MSS CRC). Likewise, in January 2021, Omega Therapeutics, Inc., which is a development-stage biotechnology company announced that it is advancing the development of OTX-2002, an Omega Epigenomic Controller development candidate to Investigational New Drug (IND)-enabling studies. It is a novel, engineered therapeutic solution particularly for controlling c-myc (MYC) oncogene expression.

 Restraints/Challenges

• High Cost of Treatment

The vast expenditure related with the epigenetics drugs impede the market growth. The treatment becomes quite unaffordable in middle-income countries, thus, in a way limiting the market growth.

This epigenetics drugs market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the epigenetics drugs market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth

COVID-19 Impact on Global Epigenetics Drugs Market

COVID-19 left a major positive impact on epigenetics drugs market. There are several researchers that are performing to understand the epigenetics to prevent viral proliferation so that vaccines and therapeutics can be developed, particularly targeting the replicating mechanisms for COVID-19 virus. Thus, the increase in the researches associated with the epigenetics positively impacts the market.     

Global Epigenetics Drugs Market Scope

The epigenetics drugs market is segmented on the basis of type of therapy, application, epigenetics diagnostic technologies, distribution channel and end-user. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Type of Therapy

• Histone Deacetylases (HDAC)
• DNA Methyltransferases (DNMT)

Applications

• Oncology
• Non-Oncology

Epigenetics Diagnostic Technologies

• DNAMethylation
• CHIP Technology

End User

• Hospitals
• Homecare
• Specialty Clinics
• Others

Distribution Channel

• Hospital Pharmacy
• Online Pharmacy
• Retail Pharmacy

Epigenetics Drugs Market Regional Analysis/Insights

The epigenetics drugs market is analyzed and market size insights and trends are provided by type of therapy, application, epigenetics diagnostic technologies, distribution channel and end-user as referenced above.

The major countries covered in the epigenetics drugs market report are the U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.

Asia-Pacific has been witnessing a positive growth for epigenetics drugs market throughout the forecasted period due to increased new research and developments on epigenetics drugs market.

North America dominates the market due to the presence of key manufacturers of the product is high and, increasing research and development activities.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.   

Competitive Landscape and Global Epigenetics Drugs Market Share Analysis

The epigenetics drugs market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to epigenetics drugs market.

Key players operating in the epigenetics drugs market include:

• Eisai Inc. (U.S.)
• Novartis AG (Switzerland)
• Chroma Medicine (U.K.)
• Syndax (U.S.)
• ValiRx Plc (U.K.)
• Merck KGaA (Germany)
• Illumina, Inc. (U.S.)
• QIAGEN (Germany)
• Hoffmann-La Roche Ltd (Switzerland)
• Abcam plc (U.K.)
• Zymo Research Corporation. (U.S.)
• Cellcentric (Germany)
• Domainex (U.K.)
• Agilent Technologies, Inc. (U.S.)
• EpiGentek Group Inc. (U.S.)
• BioVision Inc. (U.S.)
• Bio-Techne. (U.S.)
• 4SC AG (Germany)

SKU-57508